Pre-made Isecarosmab benchmark antibody ( Bispecific Single Domains (VH-VH'), anti-ADAMTSL5;ALB therapeutic antibody, Anti-THSD6;FDAHT/HSA/PRO0883/PRO0903/PRO1341 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Isecarosmab biosimilar, Bispecific Single Domains (VH-VH’), Anti-ADAMTSL5;ALB Antibody: Anti-THSD6;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Isecarosmab biosimilar, Bispecific Single Domains (VH-VH'), Anti-ADAMTSL5;ALB Antibody: Anti-THSD6;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody |
|---|---|
| INN Name | Isecarosmab |
| Target | ADAMTSL5,ALB |
| Format | Bispecific Single Domains (VH-VH') |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na;na |
| VD LC | na,na |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Merck |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ADAMTSL5,ALB |
| Package |
